Laxoberon (Sodium Picosulfate)

After oral intake, sodium picosulfate is converted by colonic bacteria into an active metabolite that stimulates the enteric nerves, increasing peristalsis and promoting water and electrolyte secretion into the intestinal lumen, thereby accelerating stool passage.

The appropriate dose of Laxoberon is determined by a qualified prescriber based on the patient’s age, condition, and response. Dosing instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

Safety of sodium picosulfate in pregnancy or lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Laxoberon.

To order Laxoberon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Laxoberon (sodium picosulfate) is a stimulant laxative that acts locally in the colon, whereas osmotic laxatives such as polyethylene glycol draw water into the bowel. Stimulant laxatives typically produce faster onset of action but may be associated with more abdominal cramping compared with osmotic agents.

Laxoberon should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme heat to maintain its stability and efficacy.

Laxoberon is taken orally, usually with a full glass of water. The tablet or granule should be swallowed whole unless the prescribing information advises otherwise. It is typically taken on an empty stomach, but patients should follow the specific instructions given by their prescriber.

Serious risks include severe dehydration, electrolyte imbalance, allergic reactions, and, in rare cases, colonic perforation especially if used in the presence of an undiagnosed bowel obstruction. Patients should seek immediate medical attention if they experience persistent vomiting, severe abdominal pain, or signs of an allergic reaction.

Laxoberon should be avoided in individuals with known or suspected bowel obstruction, acute abdominal pain of unknown cause, inflammatory bowel disease flare-ups, or hypersensitivity to sodium picosulfate. It is also contraindicated in patients for whom stimulant laxatives are medically inadvisable, as determined by a healthcare professional.